Skip to main content
. Author manuscript; available in PMC: 2015 Sep 29.
Published in final edited form as: Pediatr Blood Cancer. 2012 Jun 28;59(5):902–907. doi: 10.1002/pbc.24207

Table III.

Overall Survival (OS) and Progression-Free Survival (PFS) of Patients Treated with HDC/SCR.

N 3yr (± SE) 5yr (± SE)
Survival from time of diagnosis for all patients
PFS 33 36.4% (±8.4%) 24.2% (±7.5%)
OS 48.5% (±8.7%) 36.4% (±8.4%)
Survival from time of first transplant for patients who received at least one transplant
PFS 22 45.5% (±10.6%) 36.4% (±11.0%)
OS 59.1% (±10.5%) 45.5% (±11.2%)